China focus: BYHEALTH’s market expansion, NMN industry standards, Junlebao’s new product and more

By Tingmin Koe

- Last updated on GMT

China focus: BYHEALTH’s market expansion, NMN industry standards, Junlebao’s new product and more

Related tags China

BYHEALTH’s plan to enter the US and new Asia markets, Junlebao’s new infant formula launch, and findings from Amway’s personalised nutrition 12-week RCT are some of the latest developments covered in this China industry round-up.
Export goals: Attention turns to new Asia markets and the US – BYHEALTH International​  

BYHEALTH International is seeking opportunities in more overseas markets, including South East Asia and the US.

The firm, a part of China major nutrition company BYHEALTH, has been selling the bulk of its Australia and US-made supplements into China via the cross-border e-commerce (CBEC) channel. The products are also sold in Australia, Hong Kong, and Singapore.

Since the COVID-19 pandemic, the firm noticed that the majority of the daigous have switched to operating POP stores on CBEC channels. As such, while the firm will still focus on its CBEC sales, it is also exploring more Asian markets and the US.

Quality control: Industry sets self-regulating standards to safeguard NMN quality in China

A group of companies making nicotinamide mononucleotide (NMN) and industry big names such as hyaluronic acid specialist Bloomage Biotechnology have published a set of technical standards to safeguard the quality of NMN products sold in China.

The standards, known as ‘Product requirements and test methods for β-nicotinamide mononucleotide’​, were published on August 12.

NutraIngredients-Asia ​understands that this has been put in place as there is currently no national standards (known as Guobiao/ GB standards) regulating NMN products in China. 

High hopes: China sales surge for NZ-manufactured kids supplement Healthy Heights

Israel-based Nutritional Growth Solutions (NGS) says China sales have grown 958% quarter-on-quarter for its New Zealand-manufactured paediatric supplement Healthy Heights.

The firm entered China with their main product, the Grow Daily Kids 3+, in single-serve sachet form for children aged three to nine.

Recently, it also appointed Peter Osborne – former MD Asia for Blackmores and Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taiwan – as its strategic advisor for China and Southeast Asia.

Immune focus: China’s Junlebao increases lactoferrin content in latest infant formula launch

China’s Junlebao Dairy Group has launched a new infant formula, which is said to contain one of the highest lactoferrin content in the market.

The Shijiazhuang-headquartered company is one of the fastest-rising homegrown Chinese infant formula companies, alongside other local players such as Feihe and Yili.

Speaking to NutraIngredients-Asia, ​Celia Ning, director of Nutrition Research Institute, said that the firm has developed infant formulas with a higher lactoferrin content in view of parents’ demand for products that confer immune health benefits.

Personalised nutrition significantly improved BMI, waistlines in obese Chinese adults – Amway-funded RCT 

Personalised nutrition intervention could be more beneficial than conventional methods in improving the health statuses of overweight and obese Chinese adults, according to a 12-week RCT funded by Amway.

Some of the parameters that have improved under the intervention include BMIs, body fat percentages, waist circumferences, blood lipids and uric acid levels.

Findings of the study were published in the journal Frontiers in Nutrition.

Related topics China

Related news

Follow us


View more


Nutra Champions Podcast

Nutra Champions Podcast